Research Tracker›Biomarker Atlas›Marker Pages›H3K9Ac (chromatin marker)

H3K9Ac (chromatin marker): biomarker evidence

H3K9Ac (chromatin marker) appears in 1 entry of the OSMF biomarker atlas, covering Gulf War Illness. Across those entries it is mixed in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Gulf War Illness

Where H3K9Ac (chromatin marker) is reported

Also listed as: Epigenetic inflammation control

ConditionDirectionCompared againstAssociated symptomsSource
Gulf War Illness↕ inconsistenthealthy Gulf War veteran controlsInflammatory gene regulationJohnson et al. 2016

Frequently asked questions

In which conditions is H3K9Ac (chromatin marker) altered?

In the OSMF atlas H3K9Ac (chromatin marker) is reported in Gulf War Illness. It is mixed in 1 across 1 entries.

Is there a standard clinical test for H3K9Ac (chromatin marker)?

The atlas entries for H3K9Ac (chromatin marker) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal H3K9Ac (chromatin marker) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). H3K9Ac (chromatin marker) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/h3k9ac-chromatin-marker.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.